Lai et al. demonstrated that the introduction of the Toll/interleukin-1 receptor domain (TIR) of TLR2 to the 3’ end of CAR constructs, targeting CD19 or mesothelin, resulted in increased antitumor responses in both solid tumors and leukemia (respectively) in vitro and in vivo. Here, TLR2 is linked to leukemia.